Loading search results
difficulty of recrutement
Interest of PCT in the Management of Antibiotic for the Patient With a Febrile Pulmonary Embolism.
Sponsor study identifier
Secondary identifiers
interventional
18
1 country
1
Study Start
November 26, 2014
Actual (reported)Primary Completion
July 24, 2019
Actual (reported)Study Completion
November 24, 2019
Actual (reported)The clinical manifestations of pulmonary embolism vary greatly from the absence of specific clinical symptoms to cardiogenic shock or cardiac arrest. Clinical form of EP represented by "lung superinfection", also called "pulmonary embolism superinfected" is common and represents up to 30% of initial clinical presentations; she been few evaluations in clinical research. The reality of the bacterial infection remains controversial and the clinical presentation often leads to the prescription of empirical antibiotic therapy, often unnecessary in many cases. Number of antibiotic prescriptions are probably inappropriate. Fever has long been recognized as a sign associated with pulmonary embolism. Stein et al reported a temperature above 37.5 ° C on 50% of patients with acute pulmonary embolism without actually clarified whether this was related to temperature with a pulmonary embolism or other associated cause. Murray et al estimated that greater than 38 ° C was explained by pulmonary embolism in 57.1% of patients while in the PIOPED study, only 14% of patients had fever with no other cause identified as pulmonary embolism. Fever due to pulmonary embolism is often low intensity (often less than 38.3) and of short duration, with a peak on the day of pulmonary embolism and a gradual decrease of about 1 week. The pathophysiology of fever in pulmonary embolism has not yet was completely clarified. It is suggested that a combination of several factors involved pyrogenic myocardial tissue necrosis and releasing pro-inflammatory cytokines, hemorrhage, vascular irritation or inflammation, atelectasis or local superinfection. Since 2004, the PCT has become a marker helping the initiation of antibiotic therapy in patients with community-acquired pneumonia. This is especially verified in patients admitted for acute exacerbation of chronic obstructive bronchitis. In the latter case, the use of PCT reduces inappropriate antibiotic prescribing. Thus helping the clinician by measuring biomarkers such as PCT is based on writing an algorithm leading or not to use antibiotics. The use of an algorithm involving the PCT could just as for infectious pneumonia or COPD, of interest in the febrile pulmonary embolism to distinguish febrile forms related to bacterial infections febrile forms of EP to other causes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 24, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 5, 2014
Actual (reported)October 10, 2014
Actual (reported)November 26, 2014
Actual (reported)July 24, 2019
Actual (reported)November 24, 2019
Actual (reported)Percentage of patient treated by antibiotics in each group
at day 1
Percentage of death
at day 1
Percentage of antibiotics stop
at day 1
Rate of new hospitalization during the following month
at 1 month
In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
Farès MOUSTAFA
University Hospital, Clermont-Ferrand
18 participants (actual enrollment reported by the registry).
First Submitted
September 5, 2014
First Posted
October 10, 2014
Study Start
November 26, 2014
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
July 24, 2019
Actual (reported)Study Completion
November 24, 2019
Actual (reported)Last Updated
April 5, 2021
Record last verified: 2020-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: